American Portfolios Advisors Aim Immuno Tech Inc. Transaction History
American Portfolios Advisors
- $2.36 Trillion
- Q3 2022
A detailed history of American Portfolios Advisors transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 228 shares of AIM stock, worth $50. This represents 0.0% of its overall portfolio holdings.
Number of Shares
228Holding current value
$50% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
8.97MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$952,6000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$437,5140.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$153,6180.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$102,0830.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$100,7080.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $10.6M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...